Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
| 1 asset: 1 Ph 2 | ENERGI-F705Phase 2 · Parkinson's Disease | 1 Jan 2030ENERGI-F705 · Phase 2 | — | — | — | — | |
Enzychem Lifesciences183490 · KOSDAQ | 1 asset: 1 Ph 2 | MosedipimodPhase 2 · Atopic Dermatitis | Oct 2027Mosedipimod · Phase 2 | — | — | — | — |
Essex Bio-Technology Limited1061 · HKEX | 1 asset: 1 Ph 3 | HLX04-OPhase 3 · Age-Related Macular DegenerationPartial signal | None on record | — | — | — | — |
Everest Medicines (Beijing) Co., Ltd.1952 · HKEX | 7 assets: 2 approved, 4 Ph 3, 1 Ph 2 | LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 26 Nov 2026MT1013 · Phase 3 | — | — | — | — |
Faron Pharmaceuticals LtdPrivate | 1 asset: 1 Ph 2 | BexmarilimabPhase 2 · Higher-Risk Myelodysplastic Syndromes | Mar 2027Bexmarilimab · Phase 1/2 | — | $14MDec 2025 | — | $14M |
Foresee Pharmaceuticals6576 · TPEx | 1 asset: 1 Ph 2 | MirivadelgatPhase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease | Feb 2028Mirivadelgat · Phase 2 | — | — | — | — |
Formycon AGFYB · Xetra | 3 assets: 3 approved | Approved assets only | None on record | — | $81MDec 2025 | — | — |
Fresenius Medical Care AGFME · Xetra | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Fresenius SE & Co. KGaAFRE · Xetra | 2 assets: 2 approved | Approved assets only | None on record | — | $5.0BJun 2026 | Profitable | ~$770M |
Frontier Biotechnologies688221 · SSE STAR Market | 2 assets: 1 Ph 3, 1 Ph 2 | AlbuvirtidePhase 3 · HIVPartial signal | None on record | — | — | — | $20M |
Fuji Pharma Co., Ltd.4554.T · TSE | 1 asset: 1 Ph 3 | ColestilanPhase 3 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
GaldermaGALD · SIX | 1 asset: 1 approved | Approved assets only | Dec 2026nemolizumab · Phase 2 | — | — | — | — |
Galmed Pharmaceuticals Ltd.EOCN · Nasdaq | 1 asset: 1 Ph 3 | AramcholPhase 3 · MASH / NASH | None on record | — | $8.8MJun 2026 | ~3.2 qtrs | $5.6M |
Gan & Lee Pharmaceuticals603087 · SSE | 4 assets: 2 Ph 3, 2 Ph 2 | BofanglutidePhase 3 · ObesityPartial signal | 2 Feb 2027GZR101 · Phase 1 | — | — | — | $90M |
GC Biopharma Corp.006280 · KOSPI | 1 asset: 1 Ph 3 | Hepatitis B immune globulin (I.V.-Hepabig)Phase 3 · Chronic Hepatitis B | None on record | — | — | — | — |
Gedeon RichterRICHT · Budapest Stock Exchange | 2 assets: 2 approved | Approved assets only | 15 Dec 2026Cariprazine (Vraylar) · Phase 3 | — | — | — | — |
GemVax & KAEL082270 · KOSDAQ | 1 asset: 1 Ph 3 | TertomotidePhase 3 · Alzheimer's DiseasePartial signal | None on record | — | $15MMar 2026 | ~7.6 qtrs | ~$5.6M |
| 1 asset: 1 Ph 2 | SUL-238Phase 2 · Parkinson's Disease | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | GN-037Phase 2 · Psoriasis | None on record | — | — | — | — | |
Genenta Science S.p.A.GNTA · Nasdaq | 1 asset: 1 Ph 2 | TemferonPhase 1/2 · Glioblastoma | None on record | —no price since 3 Nov 2026 | $33MDec 2025 | ~17.0 qtrs | $3.1M |
Genentech (Roche Group)Private | 1 asset: 1 approved | Approved assets only | 31 Mar 2028Risdiplam (Evrysdi) · Approved | — | — | — | — |
GenfitGNFT · Euronext Paris | 2 assets: 1 approved, 1 Ph 2 | EzurpimtrostatPhase 1/2 · Cholangiocarcinoma with KRAS Mutation | 17 Dec 2026Elafibranor · Phase 3 | — | $119MDec 2025 | Ended Apr 2026 | $117M |
GenFleet Therapeutics2595 · HKEX | 3 assets: 1 Ph 3, 2 Ph 2 | GFH375Phase 3 · Non-Small Cell Lung Cancer | 30 Apr 2027GFH375 · Phase 2 | — | — | — | $46M |
Genovate Biotechnology4130 · TPEx | 2 assets: 2 Ph 3 | PrusogliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Genrix Bio688443 · SSE STAR Market | 3 assets: 2 Ph 3, 1 Ph 1 | Velinotamig (GR1803)Phase 3 · Multiple MyelomaWeak signal | 12 May 2027Velinotamig (GR1803) · Phase 2 | — | — | — | $66M |
GI Innovation, Inc.358570 · KOSDAQ | 3 assets: 3 Ph 2 | Efdelikofusp alfaPhase 1/2 · Non-Small Cell Lung Cancer | Feb 2027GI-108 · Phase 1/2 | — | — | — | — |
Glenmark Pharmaceuticals Ltd.GLENMARK · NSE | 3 assets: 3 Ph 3 | AlmonertinibPhase 3 · Non-Small Cell Lung CancerPartial signal | Nov 2026Trastuzumab rezetecan · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 2 | CR-001Phase 1/2 · Solid Tumors | Feb 2029CR-001 · Phase 1/2 | — | $289MSep 2026 | ~14.1 qtrs | $177M | |
GrifolsGRF · BME | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)Phase 3 | None on record | — | $970MDec 2025 | — | $483M |
GubraGUBRA · Nasdaq Copenhagen | 2 assets: 2 Ph 2 | BI 3034701Phase 2 · ObesityWeak signal | 15 Dec 2026BI 3034701 · Phase 1 | — | — | — | — |
H. LundbeckHLUN.B · Nasdaq Copenhagen | 10 assets: 8 approved, 1 Ph 3, 1 Ph 2 | BexicaserinPhase 3 · EpilepsyPartial signal | 31 Dec 2026Bexicaserin · Phase 3 | — | — | — | — |
Haisco Pharmaceutical Group002653 · SZSE | 8 assets: 5 Ph 3, 1 Ph 2, 2 Ph 1 | Anrikefon (HSK21542)Phase 3 · Chronic Kidney DiseaseReliable signal | 20 Dec 2026HSK47388 · Phase 2 | — | $267MMar 2026 | — | ~$173M |
Haleon US HoldingsPrivate | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
HanAll BioPharma009420 · KOSPI | 2 assets: 1 Ph 3, 1 Ph 1 | ImeroprubartPhase 3 · Myasthenia Gravis | May 2027Imeroprubart · Phase 2 | — | — | — | — |
Handok002390 · KOSPI | 2 assets: 1 approved, 1 Ph 3 | TeneligliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Hangzhou Zhongmei Huadong Pharmaceutical000963 · SZSE | 7 assets: 5 Ph 3, 1 Ph 2, 1 Ph 1 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | 1 Dec 2026HDM1005 · Phase 1 | — | — | — | $244M |
Hanmi Pharmaceutical128940 · KOSPI | 5 assets: 1 Ph 3, 3 Ph 2, 1 Ph 1 | efpeglenatidePhase 3 · ObesityReliable signal | Jan 2027HM15275 · Phase 2 | — | — | — | $161M |
Hansa BiopharmaHNSA · Nasdaq Stockholm | 1 asset: 1 Ph 3 | ImlifidasePhase 3 · Chronic Kidney DiseaseWeak signal | 28 Feb 2027Imlifidase · Phase 2 | — | $71MMar 2026 | ~3.3 qtrs | ~$27M |
Hansoh Pharmaceutical Group3692 · HKEX | 17 assets: 1 approved, 10 Ph 3, 3 Ph 2, 3 Ph 1 | olatorepatidePhase 3 · ObesityReliable signal | 25 Dec 2026HS-20118 · Phase 1 | — | $4.5BDec 2025 | — | $468M |
Harbour BioMed2142 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | WIN378Phase 2/3 · AsthmaWeak signal | 17 Dec 2027WIN378 · Phase 2 | — | — | — | — |
Heartseed219A · TSE | 1 asset: 1 Ph 2 | HS-001Phase 1/2 · Heart Failure | None on record | — | $40MMar 2026 | 10+ years | — |
| 1 asset: 1 Ph 3 | AlbenatidePhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — | |
Heidelberg Pharma AGHPHA · Xetra | 1 asset: 1 Ph 2 | Pamlectabart tismanitinPhase 1/2 · Multiple Myeloma | Mar 2028Pamlectabart tismanitin · Phase 1/2 | — | $38MMay 2025 | Ended Oct 2026 | ~$29M |
Hemostemix Inc.HEM · TSXV | 1 asset: 1 Ph 2 | ACP-01Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
Herantis Pharma Plc.HRTIS · | 1 asset: 1 Ph 1 | HER-096Phase 1 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
HighTide Biopharma2511 · HKEX | 1 asset: 1 Ph 3 | Berberine ursodeoxycholate (HTD1801)Phase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Hikma Pharmaceuticals PLCHIK · LSE | 3 assets: 3 approved | Approved assets only | 31 Jan 2027Cenobamate · Phase 2 | — | $217MDec 2025 | Profitable | $151M |
HK inno.N Corporation195940 · KOSDAQ | 4 assets: 3 Ph 3, 1 Ph 2 | Amlodipine/valsartan/atorvastatin (CJ-30061)Phase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
HLB Life Science067630 · KOSDAQ | 2 assets: 2 Ph 3 | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | Nov 2026Pyrotinib · Phase 1/2 | — | — | — | — |
HLS Therapeutics Inc.HLS · TSX | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Hua Medicine2552 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | DorzagliatinPhase 3 · Type 2 DiabetesPartial signal | None on record | — | $156MDec 2025 | — | $20M |
Huadong Medicine000963 · SZSE | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | Edaravone (TTYP01)Phase 3 · Acute Ischemic Stroke | Mar 2028Pamlectabart tismanitin · Phase 1/2 | — | — | Profitable | — |
Hubei Jumpcan Pharmaceutical600566 · SSE | 1 asset: 1 Ph 3 | EbronucimabPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
Huons084110 · KOSDAQ | 1 asset: 1 Ph 1 | Liraglutide (HUC2-676)Phase 1 · Obesity | None on record | — | $134MDec 2025 | — | $47M |
| 2 assets: 1 approved, 1 other | Dipyrone/Isometheptene mucate/Caffeine (Neosaldina)Migraine | None on record | — | — | — | — | |
Idorsia PharmaceuticalsIDIA · SIX | 1 asset: 1 approved | Approved assets only | None on record | — | $119MMar 2026 | Ended Oct 2026 | $123M |
IlDong Pharmaceutical Co., Ltd.249420 · KOSPI | 1 asset: 1 Ph 3 | Besifovir dipivoxil (Besivo)Phase 3 · Chronic Hepatitis BPartial signal | None on record | — | — | — | — |
Immuneering CorporationIMRX · Nasdaq | 1 asset: 1 Ph 3 | AtebimetinibPhase 3 · Pancreatic Cancer | Jun 2027Atebimetinib · Phase 1/2 | — | $145MSep 2026 | ~9.4 qtrs | $55M |
ImmuneOnco Biopharmaceuticals1541 · HKEX | 2 assets: 2 Ph 2 | Palverafusp alfaPhase 2 · Non-Small Cell Lung Cancer | 20 May 2027IMC-003 · Phase 1 | — | — | — | ~$46M |
Immunocore Holdings plcIMCR · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | brenetafuspPhase 3 · Cutaneous Melanoma | 16 Oct 2027brenetafusp · Phase 3 | — | $901MSep 2026 | 10+ years | $289M |
Imugene LimitedIMU · ASX | 1 asset: 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 | — | — | — | — |
Indivior Pharmaceuticals, Inc.INDV · Nasdaq | 3 assets: 3 approved | Approved assets only | None on record | —no price since 2 Nov 2026 | $305MSep 2026 | Cash-flow positive | $54M |
Inmagene BiopharmaceuticalsIMA · Nasdaq | 1 asset: 1 Ph 2 | OlevaprubartPhase 2 · Atopic DermatitisWeak signal | Dec 2027Olevaprubart · Phase 2 | — | $127MSep 2026 | ~13.9 qtrs | $29M |
Innate PharmaIPH · Euronext Paris | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | MonalizumabPhase 3 · Non-Small Cell Lung CancerPartial signal | Apr 2028IPH4502 · Phase 1 | — | — | — | — |
Innovent Biologics1801 · HKEX | 18 assets: 4 approved, 9 Ph 3, 3 Ph 2, 2 Ph 1 | IBI305Phase 3 · Non-Small Cell Lung CancerReliable signal | 30 Nov 2026IBI363 · Phase 2 | — | $2.6BDec 2025 | 10+ years | $387M |
Insilico Medicine3696 · HKEX | 1 asset: 1 Ph 2 | garutadustatPhase 2 · Ulcerative Colitis | 15 Aug 2027garutadustat · Phase 2 | — | $393MDec 2025 | ~4.5 qtrs | $81M |
| 1 asset: 1 Ph 1 | ISC-hpNSCPhase 1 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — | |
IntoCell, Inc287840 · KOSDAQ | 1 asset: 1 Ph 1 | ITC-6146ROPhase 1 · Non-Small Cell Lung Cancer | 30 Jun 2027ITC-6146RO · Phase 1 | — | — | — | — |
InventisBio688382 · SSE STAR Market | 4 assets: 4 Ph 3 | BefotertinibPhase 3 · Non-Small Cell Lung CancerPartial signal | 21 Nov 2026Nomelcitinib (D-2570) · Phase 1 | — | $173MJun 2026 | ~17.3 qtrs | ~$54M |
IpsenIPN · Euronext Paris | 3 assets: 3 approved | Approved assets only | 17 Dec 2026Elafibranor · Phase 3 | — | — | — | — |
IRLAB TherapeuticsIRLAB A · Nasdaq Stockholm | 3 assets: 3 Ph 2 | Mesdopetam (IRL790)Phase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
Jacobio Pharmaceuticals1167 · HKEX | 4 assets: 2 Ph 3, 2 Ph 2 | GlecirasibPhase 3 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2026JAB-23E73 · Phase 1/2 | — | $149MJun 2025 | ~18.4 qtrs | ~$26M |
JCR Pharmaceuticals4552 · TSE | 3 assets: 2 approved, 1 Ph 3 | JR-131Phase 3 · Chronic Kidney DiseasePartial signal | Dec 2026Givinostat · Phase 2 | — | — | — | — |
Jiangsu Hengrui Pharmaceuticals600276 · SSE | 116 assets: 45 Ph 3, 38 Ph 2, 26 Ph 1, 7 other | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | Nov 2026HRS-1780 · Phase 2 | — | $5.9BMar 2026 | — | ~$1.7B |
Jiangsu Nhwa Pharmaceutical Co., Ltd.002262 · SZSE | 2 assets: 1 Ph 2, 1 Ph 1 | NH102Phase 2 · Major Depressive DisorderPartial signal | None on record | — | $207MMar 2026 | — | $92M |
JW Pharmaceutical001060 · KOSPI | 7 assets: 5 Ph 3, 1 Ph 1, 1 other | AnagliptinPhase 3 · Type 2 DiabetesReliable signal | 31 Mar 2027Anagliptin · Approved | — | — | — | $48M |
Kainos Medicine284620 · KOSDAQ | 2 assets: 1 Ph 2, 1 Ph 1 | KM-819Phase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
Kaken Pharmaceutical4521 · TSE | 2 assets: 1 approved, 1 Ph 3 | EnvudeucitinibPhase 3 · PsoriasisReliable signal | 1 Dec 2027Envudeucitinib · Phase 2 | — | — | — | — |
KamadaKMDA · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | — | $75MDec 2025 | Cash-flow positive | $13M |
Kangstem Biotech217730 · KOSDAQ | 1 asset: 1 Ph 2 | Furestem-CDPhase 1/2 · Crohn's DiseaseWeak signal | None on record | — | — | — | — |
Karyopharm TherapeuticsKPTI · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | EltanexorPhase 1/2 · Multiple MyelomaWeak signal | Dec 2026Selinexor · Phase 2/3 | —no price since 10 Nov 2026 | $65MJun 2026 | ~4.0 qtrs | $121M |
Keenova TherapeuticsPrivate | 4 assets: 4 approved | Approved assets only | None on record | — | $813MDec 2025 | Ended May 2026 | ~$177M |
Keymed Biosciences2162 · HKEX | 6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1 | stapokibartPhase 3 · Atopic DermatitisReliable signal | Dec 2026Gamgertamig (CM336) · Phase 1/2 | — | $280MDec 2025 | ~3.8 qtrs | $100M |
Kiniksa PharmaceuticalsKNSA · Nasdaq | 1 asset: 1 Ph 2 | vixarelimabPhase 2 · Ulcerative ColitisPartial signal | 25 Aug 2027vixarelimab · Phase 2 | — | $569MSep 2026 | Cash-flow positive | $136M |
Kissei Pharmaceutical4547 · TSE | 7 assets: 3 approved, 3 Ph 3, 1 Ph 2 | OmarigliptinPhase 3Reliable signal | 30 Apr 2027Olutasidenib · Approved | — | $330MMar 2026 | — | $148M |
Knight TherapeuticsGUD · TSX | 6 assets: 6 approved | Approved assets only | Dec 2026viloxazine · Phase 3 | — | — | — | — |
Korea United Pharm033270 · KOSPI | 2 assets: 1 Ph 3, 1 Ph 1 | Cilostazol/rosuvastatin (UI022/UI023)Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record | — | — | — | — |
Krystal Biotech, Inc.KRYS · | 4 assets: 1 approved, 1 Ph 2, 2 Ph 1 | KB707Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026KB407 · Phase 1 | — | $912MSep 2026 | Cash-flow positive | $60M |
Kureha Corporation4023 · TSE | 1 asset: 1 Ph 3 | AST-120Phase 3 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
Kwang Dong Pharmaceutical009290 · KOSPI | 1 asset: 1 Ph 2 | bremelanotidePhase 2 · ObesityReliable signal | None on record | — | $98MDec 2025 | — | $6.4M |
Kyowa Kirin4151 · TSE | 9 assets: 6 approved, 3 Ph 1 | KK2269Phase 1 · Non-Small Cell Lung Cancer | Dec 2026Ziftomenib · Phase 1 | — | $1.4BDec 2025 | — | $676M |
Laboratorios Farmacéuticos Rovi, S.A.ROVI · BME | 1 asset: 1 Ph 1 | Risperidone (QUAR)Phase 1 · SchizophreniaWeak signal | None on record | — | — | — | — |
Laekna Limited2105 · HKEX | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | AfuresertibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | 30 Jun 2027LAE102 · Phase 1 | — | $165MJun 2026 | 10+ years | ~$28M |
Lee's Pharmaceutical0950 · HKEX | 4 assets: 2 Ph 3, 1 Ph 2, 1 other | Loxapine (Adasuve)Phase 3 · SchizophreniaReliable signal | Dec 2028Istaroxime · Phase 2/3 | — | $45MDec 2025 | — | $14M |
LG Chem051910 · KOSPI | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027LB-LR1109 · Phase 1 | — | — | — | — |
Lifeward Ltd.LFWD · Nasdaq | 1 asset: 1 Ph 3 | ORMD-0801Phase 3 · Type 2 DiabetesPartial signal | None on record | — | $5.0MSep 2026 | ~1.0 qtrs | $10M |
LigaChem Biosciences, Inc.141080 · KOSDAQ | 2 assets: 1 Ph 2, 1 Ph 1 | LCB84Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027LCB84 · Phase 1/2 | — | — | — | — |
Livzon Pharmaceutical Group Inc.000513 · SZSE | 1 asset: 1 Ph 3 | LecankitugPhase 3 · Psoriasis | None on record | — | — | Profitable | — |
Lundbeck LLCPrivate | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Lupin LimitedLUPIN · NSE | 3 assets: 2 approved, 1 Ph 3 | BofanglutidePhase 3 · ObesityPartial signal | 30 Jun 2027Bofanglutide · Phase 3 | — | — | Profitable | $233M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.